DNDN update:
In message #17742, from last October, I said:
>>
Here are some other predictions:
1. DNDN will not in the near future be able to attract a commercialization partner for Provenge on the kinds of terms one would ordinarily expect for a post-phase-3 product in a large medical indication such as prostate cancer.
2. One or more additional senior executives will leave the company before the BLA is approved.
3. DNDN will talk less often about its manufacturing buildout because these plans will be moved to the back burner.
JMHO, FWIW. If I’m wrong, I’ll be the first to admit it.
<<
Five months later, prediction #1 and, especially, prediction #2 look like they were spot-on. Moreover, the DNDN stock price has continued its relentless decline and now sits at a new multi-year low.
Speaking empirically, I think my comments vis-à-vis DNDN have been more reliable than those of one of the other regular posters here.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
